An improvement of NASH, ALT/AST, intrahepatic triglyceride levels, and fibrosis using the fibrosis-4 (FIB-4) score has been shown with canagliflozin [56,57]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.